IO Biosciences

Executive Summary

IO Biosciences is a preclinical biotechnology company developing off-the-shelf Natural Killer (NK) cell therapies for cancer, with an initial focus on liver cancer. Its proprietary GEMS™ platform enables efficient, plug-and-play genetic modification of NK cells, facilitating scalable manufacturing and potential for multiple therapeutic programs. The company operates a hybrid business model, advancing its own pipeline while offering platform licensing to partners. As a private, early-stage company with 11-50 employees, IO Biosciences has not disclosed funding or valuation. Its technology addresses key challenges in cell therapy, including allogeneic sourcing and manufacturing simplicity, positioning it for potential partnerships or clinical milestones.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead NK Cell Therapy Candidate30% success
• Q2 2026Preclinical Efficacy Data Presentation at Major Conference60% success
• Q4 2026Strategic Partnership or Platform Licensing Deal40% success